Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

APG-115 (alrizomadlin)

NCT03781986

University of Michigan · Phase 1/2 · Active, not recruiting · Enrollment 41

NCT03781986

Catalyst Primary completion. 01.19.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.